분자유전학실험실 (단국대학교 분자생물학과)



 이성욱 ( 2017-02-24 03:47:12 , Hit : 1290
 CRISPR Turbocharges CAR T Cells, Boosts Cancer Immunotherapy

GEN News Highlights
More »
February 23, 2017

http://www.genengnews.com/gen-news-highlights/crispr-turbocharges-car-t-cells-boosts-cancer-immunotherapy/81253925?utm_medium=newsletter&utm_source=GEN+Daily+News+Highlights&utm_content=01&utm_campaign=GEN+Daily+News+Highlights_20170223


In a model of acute lymphoblastic leukemia, CAR T cells created with CRISPR outperformed those made with technology that relies on randomly integrating vectors.

When T cells are modified to fight cancer more effectively, cellular mechanics don’t pick up a socket wrench. Instead, they take hold of retroviral or lentiviral technology, which is used to install genes for synthetic T-cell receptors. Such technology, however, doesn’t always place genes in just the right place. Enter Mr. GoodCRISPR. This mechanic uses CRISPR gene-editing technology, which is more precise.

CRISPR can be used to install genes, such as chimeric antigen receptor (CAR) genes, into specific parts of the genome. Presumably, when CRISPR is used to build CAR T cells, their genomic engines will run more smoothly—and rack up more trouble-free miles. Such endurance is important for CAR T cells, which are being used in immunotherapy applications. These are long-distance races, and they are particularly grueling when CAR T cells must outpace cancer.

A road test of sorts has been staged by scientists based at Memorial Sloan Kettering Cancer Center (MSK). They decided that CRISPR T-cell engineering might be more effective than conventional T-cell engineering, which, the scientists have observed, can result in clonal expansion, oncogenic transformation, variegated transgene expression, and transcriptional silencing.

The scientists built CRISPR-engineered CAR T cells and evaluated their efficacy in a model of acute lymphoblastic leukemia. The results of this work appeared February 22 in Nature, in an article entitled, “Targeting a CAR to the TRAC Locus with CRISPR/Cas9 Enhances Tumour Rejection.” As the title suggests, the MSK team took advantage of CRISPR’s ability to deliver genes to selected genomic loci.

“Here we show that directing a CD19-specific CAR to the T-cell receptor α constant (TRAC) locus not only results in uniform CAR expression in human peripheral blood T cells, but also enhances T-cell potency, with edited cells vastly outperforming conventionally generated CAR T cells in a mouse model of acute lymphoblastic leukaemia,” wrote the article’s authors. “We further demonstrate that targeting the CAR to the TRAC locus averts tonic CAR signalling and establishes effective internalization and re-expression of the CAR following single or repeated exposure to antigen, delaying effector T-cell differentiation and exhaustion.”

Essentially, the MSK team showed that CRISPR technology can deliver a CAR gene to a very specific location in the genome of the T cell. Moreover, the team demonstrated that this precise approach resulted in CAR T cells that had more stamina.

The CRISPR-modified T cells are able to kill tumor cells for longer because they are less prone to exhaustion. More robust T cells could eventually lead to safer, more effective use of cell-based immunotherapy in patients.

"Cancer cells are relentless in their attempt to evade treatment, so we need CAR T cells that can match and outlast them," explained Michel Sadelain, M.D., Ph.D., senior author on the Nature paper and director of the Center for Cell Engineering and the Gene Transfer and Gene Expression Laboratory at MSK. "This new discovery shows that we may be able to harness the power of genome editing to give these 'living therapies' a built-in boost. We are eager to continue exploring how genome-editing technology could give us the next generation of CAR T cell therapy."

Some of the first clinical trials using CRISPR technology are currently in the planning stages. Dr. Sadelain and his team aim to eventually explore the safety and efficacy of these CRISPR-built CAR T cells in a trial.







1007   CRISPR Platform Scans DNA to Predict Off-Target Effects  이성욱 2017/07/02 1127
1006   Fixing CRISPR  이성욱 2017/06/27 1005
1005   [미국] 듀폰, 유전자가위 기술 적용 옥수수 출시를 위한 노력  이성욱 2017/06/22 911
1004   [바이오토픽] CRISPR를 역이용하는 파지(phage), 항생제내성 세균을 물리치는 신무기  이성욱 2017/06/22 1167
1003   [바이오 업계 소식: From Startups to Moguls] CRISPR-Cas9에 대한 경고와 업계 반응  이성욱 2017/06/14 697
1002   Was a Drop in CRISPR Firms’ Stock Warranted?  이성욱 2017/06/09 1208
1001   First In Vivo Human Genome Editing to Be Tested in New Clinical Trial  이성욱 2017/05/18 769
1000   독감바이러스의 ‘RNA 도둑질’  이성욱 2017/05/08 804
999   More Tooth, More Tail in CRISPR Operations  이성욱 2017/04/25 902
998   Gut Microbes Contribute to Age-Associated Inflammation in Mice  이성욱 2017/04/14 1393
997   CRISPR Corrects Duchenne-Causing Mutations  이성욱 2017/04/14 840
996   Scientists unveil CRISPR-based diagnostic platform  이성욱 2017/04/14 813
995   [사이언스 카페] 美 FDA, 민간업체의 '개인용 유전자 검사' 첫 허용  이성욱 2017/04/10 797
994   암 전이에 핵심 역할하는 줄기세포 찾았다  이성욱 2017/04/03 1164
993   ‘단세포 인공생명체’ 눈앞에 성큼  이성욱 2017/03/11 795
992   Beyond CRISPR Cuts: Five Complements To Cas9  이성욱 2017/02/24 986
991   Smallest CRISPR So Far Comes from Food Poisoning Bacteria  이성욱 2017/02/24 925
  CRISPR Turbocharges CAR T Cells, Boosts Cancer Immunotherapy  이성욱 2017/02/24 1290
989   [바이오토픽] 브로드 연구소, 열띤 CRISPR 특허전쟁에서 승리  이성욱 2017/02/16 1059
988   Judges Side with Broad Institute in CRISPR Patent Dispute  이성욱 2017/02/16 954

[이전 10개] [1]..[11][12][13] 14 [15][16][17][18][19][20]..[64] [다음 10개]
 

Copyright 1999-2021 Zeroboard / skin by ROBIN